Diet and Age Interactions with Regards to Cholesterol Regulation and Brain Pathogenesis by Uranga, Romina M. & Keller, Jeffrey N.
Hindawi Publishing Corporation
Current Gerontology and Geriatrics Research
Volume 2010, Article ID 219683, 14 pages
doi:10.1155/2010/219683
Review Article
Dietand Age Interactions with Regards to Cholesterol Regulation
andBrain Pathogenesis
Romina M. Uranga1,2 andJeffrey N. Keller2
1Instituto de Investigaciones Bioqu´ ımicas de Bah´ ıa Blanca, Universidad Nacional del Sur and Consejo Nacional de Investigaciones
Cient´ ıﬁcas y T´ ecnicas, Bah´ ıa Blanca, Argentina
2Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton Rouge, LA 70820, USA
Correspondence should be addressed to Jeﬀrey N. Keller, jeﬀrey.keller@pbrc.edu
Received 8 December 2009; Accepted 15 February 2010
Academic Editor: Jacek Witkowski
Copyright © 2010 R. M. Uranga and J. N. Keller. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Cholesterol is an essential molecule for brain homeostasis; yet, hypercholesterolemia and its numerous complications are believed
to play a role in promoting multiple aspects of brain pathogenesis. An ever increasing number of individuals in modern
Western Society are regularly consuming diets high in fat which promote the development of hypercholesterolemia. Additionally,
modern societies are becoming increasingly aged, causing a collision between increased hypercholesterolemia and increased aging,
which will likely lead to the development of increased pathological conditions due to hypercholesterolemia, thereby promoting
deleterious neurochemical and behavioral changes in the brain. Lastly, while beneﬁcial in controlling cholesterol levels, the long-
term use of statins itself may potentially promote adverse eﬀects on brain homeostasis, although speciﬁcs on this remain largely
unknown. This review will focus on linking the current understanding of diet-induced hypercholesterolemia (as well as statin use)
to the development of oxidative stress, neurochemical alterations, and cognitive disturbances in the aging brain.
1. Overview of Cholesterol
Cholesterol is an essential component of cell membranes
which plays an important role in the maintenance of
cellular homeostasis and transmembrane communication
within, and between cellular compartments [1]. Choles-
terol biosynthesis is a multistep process which takes place
mainly in the liver and the intestine, and involves more
than twenty enzyme-catalyzed reactions for converting
acetate into cholesterol (Figure 1). The rate limiting reaction
in cholesterol biosynthesis is catalyzed by 3-hydroxy-3-
methylglutaryl-CoA (HMGCoA) reductase, and it is this
enzymatic step which has been used as pharmacological
target of statin treatments (see below).
Since cholesterol is insoluble in water, it is transported
in blood through complex micelle-like amalgamations of
various proteins and lipids. These particles, referred to as
lipoproteins, are heterogeneous in size, shape, composition,
function, and are diﬀerentially linked to vascular disease
[2]. High-density lipoprotein (HDL) particles, commonly
referred to as “good cholesterol”, promote vascular health
by taking cholesterol out from tissues and delivering it
back to the liver, resulting in the elimination of excess
cholesterol from the body. This process is at the center
of HDL-mediated prevention of low-density lipoprotein
(LDL)-cholesterol build up within arterial walls. Levels of
HDL cholesterol below 35mg/dL represent a substantially
higher risk for coronary heart disease [3, 4], and there-
fore maintaining HDL cholesterol levels about 35mg/dL
is necessary to maintain overall health. LDL particles,
also referred to as “bad cholesterol”, carry most of the
cholesterol in the circulation and tend to be readily oxidized
and bind to connective tissue in the intimal sublayer of
arteries [5, 6]. Thus, the higher LDL cholesterol in blood,
the greater the risk of subsequent cardiovascular disease.
Before reaching a particle of the HDL or LDL subfraction,
cholesterol molecules will usually undergo a maturation
process beginning with the hepatic or intestinal synthesis
of very low density lipoprotein (VLDL) particles. These
lipoproteins not only contain cholesterol but also contain
fatty acids (esteriﬁed to triglycerides), phospholipids, and
apolipoproteins [2].2 Current Gerontology and Geriatrics Research
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Figure 1: Schematic colesterol biosynthetic pathway. Statins lower
cholesterol synthesis by inhibiting 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase.
2.HighFatDiets andAge-RelatedChanges
inCholesterolMetabolism
The eﬀects of high fat diets (HFDs) on cholesterol
metabolism have been studied in both humans and animals.
HFD consumption has been associated with hyperlipi-
demia. Studies performed in humans have shown that HFD
consumption causes an increase in both total and LDL
cholesterol levels in plasma, a signiﬁcant reduction in HDL
cholesterol, and an increased total cholesterol=HDL choles-
terol ratio [7]. Erythrocyte and leukocyte membranes were
observed to have increased cholesterol and phospholipid
content following HFD consumption, and demonstrated to
have an elevated cholesterol=phospholipid molar ratio [7].
Interestingly, these metabolic alterations are reversed slowly
after returning to a normal (low-fat) diet.
A clear increase in plasma cholesterol levels has been
found in all mammals, including humans, during the
suckling period [8]. An increase, as well as a decrease, in the
levels of blood cholesterol has also been observed following
weaning depending on the diets consumed postweaning [9].
Taken together with many studies carried out in diﬀerent
populations, it is clear that plasma lipid levels in adults
are attributable to the quality and quantity of dietary lipid
intake. People consuming a diet that is balanced and low
in fat exhibit low total cholesterol and low LDL cholesterol
levels [10–12]. However, when these people are placed on
more typical Western diets (high in fat), their total and LDL
c h o l e s t e r o ll e v e l si n c r e a s e[ 10, 13].
It is believed that cholesterol turnover is strongly cor-
related with body fat. For example, it has been shown
that cholesterol turnover is higher in obese individuals as
compared with nonobese subjects, and that the excess of
body fat correlates signiﬁcantly with the daily production
of cholesterol [14]. It is thought that diﬀerent levels of
cholesterol and adiposity following HFD consumption could
be due to adipocyte number, cell membrane phospholipids
and glycoproteins, and cholesterol-esterifying activity in
cells, all of which are capable of modulating adiposity and
cholesterol levels following HFD consumption [7]. Long-
term HFD consumption leads to a signiﬁcant increase
not only in body weight but also an increase in serum
concentrations of triglycerides and cholesterol [15]. Inter-
estingly, studies carried out in hypercholesterolemic rabbit
model of atherosclerosis and Alzheimer’s disease (AD) have
demonstrated that high-cholesterol diet is able to induce
signiﬁcant increases in plasma and liver cholesterol, but
did not signiﬁcantly alter brain cholesterol levels [16]. It
is not yet fully known how cholesterol may modulate the
susceptibility to neurological disorders. It is well known that
high cholesterol levels in plasma are suﬃcient to promote
atherosclerosisinlargearteries[17]andthereisalsoevidence
showing that high cholesterol adversely aﬀects the function
of the microvasculature, including microvessels in the brain
[18]. In this regards, Franciosi and coworkers have reported
that mice fed high-cholesterol diet develop a vascular
pathology that aﬀects the central nervous system (CNS)
microvasculature [19]. This vascular pathology seems to be
diﬀerentfromcholesterol-inducedatherosclerosisandshares
some features with the microvascular pathology commonly
associated with AD [20]. Further studies on this issue are
important for clarifying the role of cholesterol in mediating
the vascular pathology observed in neurodegenerative dis-
e a s e ss u c ha sA D .
When discussing cholesterol disturbances in relation to
age-related diseases of the nervous system, it is important to
consider aging-induced changes in cholesterol metabolism.
A number of metabolic changes have been reported to
occur during normal aging in both animals and humans
[21]. Reduced physical activity, redistribution of body tissues
with a relative increase in adipose over muscle mass [22],
increased insulin resistance [23, 24], and increased blood
pressure [25] are all factors that could contribute to the
acceleration of age-related atherosclerosis. Plasma levels of
total and LDL-cholesterol are well known to increase with
normal aging both in humans and rodents [26–29], and the
plasma clearance of LDL has been shown to decrease with
age in both humans and rodents [26, 28, 30], with high
plasma LDL-cholesterol levels being key causal factors for
the onset of atherosclerosis and coronary heart disease. This
observation may be related to the decreased breakdown of
cholesterol to bile acids reported to occur in aging rodents
[29, 31], as well as to the increased intestinal cholesterol
absorption in aging mice and rats [31, 32]. Additionally, it
has been reported that cholesterol metabolism is markedly
modiﬁed during normal aging [33], and in humans plasma
LDL-cholesterol increases by about 40% from 20 to 60 years
of age [34]. Important to point out is the role of growth
hormone in cholesterol metabolism. It has been shown that
growth hormone has key roles in lipid metabolism in adult
humans and animals [35–37], particularly in some steps of
cholesterol metabolism. In this regards, it has been reported
that the secretion of growth hormone is reduced with
aging [21, 38], and experiments performed in rodents have
demonstrated that the administration of growth hormoneCurrent Gerontology and Geriatrics Research 3
is able to completely reverse the age-dependent increase
in plasma cholesterol, as well as the reduced level of bile
acid synthesis to the same levels as seen in young animals
[29]. Taken together, these data clearly suggest that the
decreased secretion of growth hormone during aging may
be a causal factor contributing to the age-dependent rise in
serum cholesterol.
3. Cholesterol, Cholesterolemia, andthe Brain
Cholesterol is a well-known key regulator of membrane lipid
organization and ﬂuidity, and thus homeostatic mechanisms
to maintain cellular cholesterol levels in membranes are
essential for life. Even though the CNS represents only 2.2%
of body weight, it contains as much as 23% of total body
cholesterol [8]. Interestingly, the half-life of brain cholesterol
is 6 months–5 years [39–41], in contrast to its half-life in
plasma which is measured in hours [1, 8, 42–46].
The synthesis of cholesterol in the brain occurs mainly in
olygodendrocytes and astrocytes [42]. While it is well known
that oligodendrocytes generate cholesterol for the myeli-
nation process, it has been shown that astrocytes produce
cholesterol for neuronal cells, using a transport system that
involves ATP-binding cassette A1 (ABCA1) and ATBCG1
transporters [47–49]. These transporters are expressed in
neurons, astrocytes and microglia as well, and are necessary
for maintaining the physiological levels and production of
lipoproteins secreted by astrocytes and microglia [49, 50].
Active axonal growth, as well as synapse formation and
remodeling, requires cholesterol that cannot be provided by
the distant cell body of the neuron. Cholesterol for these
processes may be derived primarily from astrocytes, via the
synthesis and secretion of ApoE-associated cholesterol at
sites near the axonal growth and synapse formation [51].
It has been suggested that neurons, during development,
are able to synthesize most of the cholesterol they need for
growth and synaptogenesis [46]. However, as soon as they
mature, they have an impairment in this process and grow
to depend on cholesterol provided by astrocytes [1, 52]. This
reduction in endogenous neuronal cholesterol biosynthesis
inadultbrainslikelyresultsfromthelargemetabolicrequire-
ment for the biosynthesis of cholesterol, and the need for
optimalenergyeﬃciencywithintheCNS.Interestingly,ithas
been shown that brain-derived neurotrophic factor (BDNF)
is an important stimulus for neuronal de novo synthesis of
cholesterol [53]. Since cholesterol has structural features that
make membranes more rigid, maintaining the proper level
of cholesterol is essential for neuronal membrane function,
especially at the synaptic endings, where membrane ﬂuidity
inﬂuences the process of neurotransmission [54].
The cholesterol resident within the brain exists in two
pools. The major pool accounts for approximately 70% of
the total brain cholesterol, is metabolically stable, and is
found in the myelin membranes of white matter [55, 56].
Theconcentrationofcholesterolinthispoolisabout40mg/g
tissue and reﬂects the dense packing of multiple opposed
lipid bilayers in the myelin sheath [57]. The second pool of
cholesterol is less abundant, about 30% of total cholesterol
pool, and is found in the plasma and subcellular membranes
of neurons and glial cells within the grey matter [57]. The
concentration of cholesterol in this pool is lower (8mg/g),
and it is metabolically active and in an unesteriﬁed form.
Many of the same proteins involved in the movement of
cholesterol throughout the body are also expressed in the
CNS including many members of the LDL receptor family
as well as scavenger receptor class B type I (SR-BI) [58, 59].
The apolipoproteins ApoE, ApoA-I, ApoA-IV, ApoD, and
ApoJ have also been reported in cerebrospinal ﬂuid (CSF),
and various members of the ABC family of transporters are
expressed in speciﬁc cells of the CNS [60, 61]. Interestingly,
any lipoprotein-carried cholesterol that enters or leaves the
CNS must cross the blood brain barrier (BBB), which
anatomically is made up of unique endothelial cells whose
basal membranes are also intimately associated with the foot
processes of adjacent astrocytes [62]. Capillaries of the brain
appear to have no fenestrae and show very little capability
for bulk phase vesicular transport [8]. Moreover, adjacent
endothelialcellsaretightlyadherent,soitisveryunlikelythat
cholesterol carried in lipoproteins can reach the CNS either
throughfenestrationsinthecapillarymembranesorthrough
paracellular diﬀusion [63, 64]. From this point of view,
it would appear that circulating cholesterol has a minimal
contribution to levels of cholesterol in the adult brain.
However, several studies have determined that circulating
levels of cholesterol do have direct consequences on the
brain. For example, a physiological hypercholesterolemia is
observed during suckling [8], and this is at the time of
major growth and myelination in brain, so restrictions in
diet cholesterol are thought to be deleterious for later brain
development and performance [65, 66]. Moreover, many
investigations have reported that adults with low-blood
cholesterol exhibit aggressive, suicidal, or criminal behavior
[67–70], and the possible cause could be a reduction in the
number of serotonin receptors in brain as a consequence
of a loss of cholesterol in membranes [71]. In addition, it
has been found that there is a positive correlation between
plasma cholesterol levels and the incidence of dementias and
AD [72–74]. Taking into account that plasma lipoprotein-
carried cholesterol pool does not cross the BBB, the question
is how would cholesterolemia have consequences in brain
performance? Firstly, it is possible that plasma membrane of
endothelial cells contain functional lipoprotein transporters
or transporters for unesteriﬁed cholesterol like ABCA1.
Secondly, it is possible that a small amount of bulk-
phase endocytic transcellular movement could take place
in endothelial cells. Thirdly, it has been demonstrated that
the BBB is permeable to some hydrophobic molecules such
as sterols and that hydroxylation of sterols greatly increases
their rate of passive diﬀusion across the BBB [8]. In fact,
brain 27-OH cholesterol has been found to correlate with
plasma cholesterol levels, so it is believed to maintain
cholesterol homeostasis within the brain [40, 41, 75]. In
this regard, it is possible that unesteriﬁed or hydroxylated
cholesterol could diﬀuse passively across the BBB through
existing gradients [8, 76]. Further research is necessary to
address this issue and to clarify the mechanisms by which
levels of circulating cholesterol “communicate”/relate with
those present in brain.4 Current Gerontology and Geriatrics Research
4.ApoEandBrain
ApoE is one of the major apolipoproteins in plasma and the
principal cholesterol carrier protein in the brain. In recent
years, brain cholesterol and ApoE have been intensively
explored in relation to brain aging and age-related diseases
of the brain. Studies with transgenic mice lacking ApoE
(ApoE
−/−)havedemonstratedthatthelossofApoEincreases
behavioral deﬁciencies, oxidative stress, synaptic dysfunc-
tion, and enhanced pathogenesis following brain injury [77–
80]. Taken together, these data clearly implicate ApoE in the
regulation of brain pathogenesis.
While plasma ApoE originates predominantly from the
liver and macrophages, the brain is able to locally synthesize
it, and plasma pool of ApoE does not appear to readily
exchange with the brain pool owing to the presence of
the BBB [8, 81, 82]. Astrocytes are the main ApoE source
in brain, although neurons and microglia are also able
to synthesize it in some pathological conditions [44, 83–
85]. Astrocytes secrete ApoE in discoidal HDL particles
composed of phospholipids and unesteriﬁed cholesterol. It
appears that before reaching the CSF some of these particles
accumulatecholesterolandformsphericallipoproteinsupon
esteriﬁcation of free cholesterol [86].
ApoE in the brain is associated to the only lipoproteins
found in the CNS, the HDL-like lipoproteins [60, 87–89].
Other apolipoproteins are also found in the brain: ApoA-
I, ApoA-II, ApoA-IV, ApoD, ApoE, ApoH, and ApoJ, being
ApoE the predominant [90] .A p o Ei se x p r e s s e di ns e v e r a l
organs, with the highest expression in the liver, followed by
the brain. Interestingly, ApoE-containing lipoproteins in the
CSF are produced predominantly, if not exclusively, by cells
within the CNS [82]. Although neurons are able to produce
ApoE in some situations, it is mainly expressed by astrocytes
and to some extent microglia [84, 87, 90–95].
In humans, ApoE gene contains several single-nucleotide
polymorphisms distributed across the gene [96]. The most
common three polymorphisms result in the three common
isoforms ApoE2, ApoE3, and ApoE4, and although they
diﬀer only in one or two aminoacids, they deeply diﬀer
in structure and function [97]. Several studies have shown
that ε4 allele is a strong risk factor for both AD and
cerebral amyloid angiopathy (CAA), whereas the ε2a l l e l e
is associated with decreased AD risk [98–102]. It has been
suggested that the eﬀe c to fA p o Ei s o f o r m so nA Da n d
CAA would be mediated by interactions between ApoE and
the amyloid-β (Aβ)p e p t i d e[ 103], altering the peptide’s
clearance and ﬁbrillogenesis [104–107]. Based on the strong
association between ApoE and Aβ in the brain [108], it
was hypothesized that ApoE may function as an Aβ-binding
protein that induces a pathological β sheet conformational
change in Aβ [102]. It is not known yet if the ApoE2
protective eﬀect is due to modulation of Aβ aggregation or
to an alternative mechanism independent of amyloid plaque
formation [109]. Most studies have demonstrated that the
eﬃciency of complex formation between ApoE and Aβ is
ApoE2 > ApoE3   ApoE4 [110]. As these data represent
an inverse correlation with the risk of developing AD, it
has been suggested that ApoE2 and ApoE3 may enhance the
clearance of Aβ, compared to ApoE4. It has also been shown
that the three isoforms of ApoE promote Aβ42 ﬁbrillization,
with the maximal ﬁbrillization occurring with the ApoE4
isoform, and minimal with ApoE2 [111]. Other studies
using transgenic mice that possess diﬀerent human ApoE
transgeneshavealsodemonstratedthatAβ depositionoccurs
in an isoform-dependent manner (E4 > E3) [112, 113].
Interestingly, experiments performed in Tg2576 mice, which
have human ApoE3 and ApoE4 as knock-in genes, have
shown that both human ApoE isoforms delayed the onset
of Aβ deposition relative to control mice not having the
human genes, with human ApoE4 promoting more amyloid
deposition and CAA than human ApoE3 [114]. Important
to note, complexes of Aβ and ApoE2 or ApoE3 are cleared
out of the brain signiﬁcantly faster than complexes of Aβ
and ApoE4 [115]. All these data clearly support the idea that
ApoE promotes Aβ deposition, with ApoE4 promoting the
most severe eﬀect. However, these studies do not exclude the
possibility that all three ApoE isoforms are inhibitors of Aβ
aggregation, with ApoE4 being the least eﬀective [100].
5. Cholesterol and SynapticFunction
Aging is the major risk factor not only for AD but for
other neurodegenerative disorders as well. Therefore, before
moving on to discussing the roles of cholesterol and ApoE
in the pathophysiology of neurodegeneration, it is worth
spending a moment to understand the changes in cholesterol
and ApoE during normal aging. Many studies have reported
the decrease in weight and size of human brain during
aging [116], and it is suspected that these changes are
due to reduction in neuronal size and in synapse number,
bothparametersassociatedwithcognitiveimpairment[117].
Brain cholesterol levels do not change in a uniform manner
inthebrain,instead,thechangesvaryaccordingtotheregion
studied. Some regions do not show any change while others
show a decrease of 40% [118]. It has been also reported that
thereisadecreaseinthecontentofcerebralcortexcholesterol
throughout life, and this decrease would represent the loss of
axons and processes in the cerebral cortex [119].
As stated above, cholesterol is crucial for synapse genera-
tion, since it increases the number of synaptic vesicles, which
contain high levels of cholesterol [120–122]. Additionally,
cholesterol is considered to be essential for remodeling
neuronal membranes and growing new terminals, either
during synaptic plasticity or in response to a neurodegen-
erative insult. Moreover, if cholesterol is not supplied by
astrocytes, neurotransmission is deleteriously aﬀected. It has
been suggested that the molecular basis of this phenomenon
is related to the failure in the formation of lipid rafts in
the absence of cholesterol [51]. Lipid rafts are believed to
be essential for intracellular signaling, as they concentrate
the signaling pathways at membranes, and they seem to be
particularly important at the synapse level. In this regard,
it has been reported that the absence of cholesterol causes
loss in synaptic endings and dendritic spines [51]. So it
could be speculated that the cognitive decline observed
during aging could be related to the decrease in synapticCurrent Gerontology and Geriatrics Research 5
transmission, and this could be associated, at least in part,
with the age-related decrease of brain cholesterol. On the
other hand, cholesterol has been shown to enhance the
eﬃcacy of presynaptic transmitter release, enable dendrite
diﬀerentiation, and promote the redistribution of glutamate
receptors [123]. Additionally, as neurons are not able to
produce suﬃcient amounts of cholesterol on their own, they
may need cholesterol provided from astrocytes as building
material for dendrites and synapses [124].
In addition, it has been reported that ApoE levels
might be important for brain homeostasis during aging.
AlthoughitisnotclearwhetherApoEexpressioninthebrain
changes with aging, some studies in rodents have shown
that the expression of this apolipoprotein is decreased in
hypothalamus and cortex [125], however, it is increased in
the hippocampus [126]. It is suspected that ApoE plays a key
role in spatial learning and memory process, since studies
carried out in ApoE-null mice have shown that infusion
of ApoE via the intracerebroventricles is able to revert the
memory and spatial learning impairment caused by the lack
of ApoE [127].
In regards to synaptic plasticity, many studies have
been carried out in ApoE knockout (KO) mice. In vivo
neurophysiologicalstudiesinthehippocampusofagedApoE
KO mice have shown that the absence of ApoE generates a
decrease in long-term potentiation [128]. Moreover, Krugers
and coworkers have also reported altered synaptic plasticity
in ApoE KO mice, with deﬁcits in long-term potentiation
[129]. All these evidence clearly suggest that behavioral and
neuropathological alterations observed in ApoE KO mice
could be related to alterations in synaptic plasticity. The
mechanism by which ApoE would alter synaptic plasticity
remainsunclear,althoughsomerecentevidencesuggeststhat
it would be related to calcium regulation [130]. In addition,
ApoE2 overexpression has been shown to protect against
dendritic spine loss reported to occur in the hippocampus
of young amyloid precursor protein (APP)-transgenic mice.
Many in vivo studies have shown that ApoE3 is able
to increase synaptic plasticity and exert neuroprotective
eﬀects, whereas results about ApoE4 eﬀects on synaptic
plasticity are inconsistent. Some studies say that ApoE4
has a negative eﬀect on neurites and synaptic functions
[131] and others propose that it may have beneﬁcial eﬀects
[127, 132]. Further studies would be needed to clarify this
issue.
6. Cholesterol and CerebralBlood Vessels
It has been shown that hypercholesterolemia can result in
the damage to endothelial cells of arteries and capillary
vessels, decrease in blood ﬂow, impairment of metabolism,
and the decrease in nutritive and oxygen levels in the
brain [133], thus increasing the possibility of cognitive
impairment. It is well known that hypercholesterolemia
and hypertension are two of the most common age-
related metabolic disturbances. It has been reported that
hypercholesterolemia and/or hypertension impair endothe-
lialfunctioninperipheralvasculature.However,theirimpact
on endothelial cells of brain microvessels is unclear. Some
studies have shown that hypertension would increase BBB
permeability, and the extent of that increase has been shown
to be smaller in hypercholesterolemic animals with acute
induction of hypertension than that observed in chronically
hypertensive animals [134]. In addition, it has been reported
that subjects with familial hypercholesterolemia have at least
20 times higher risk of brain infarction than in the general
population, so subjects with familial hypercholesterolemia
have not only a high risk of coronary heart disease but also
a high risk of cerebrovascular disorders [135]. On the other
hand, alteration of cerebral blood ﬂow and hypoperfusion
of brain regions due to arteriosclerosis of the cerebral
vasculature might precede frank dementia by many years
[136]. In this regard, it has been reported that even small
asymptomatic cerebral infarcts can increase the probability
of expressing clinical symptoms of dementia by 20 times in
individuals with existing senile plaques and neuroﬁbrillary-
tangles [137].
An additional link between cholesterol and AD is that
cholesterol has been also associated with CAA, a highly
prevalentdisorderinADwhereAβ depositsincerebralblood
vessel walls. It has been suggested that ApoE-cholesterol-
lipoprotein complex would be involved in the process of Aβ
deposition. ApoE ε4 allele has been strongly associated with
the increase in vascular deposition of Aβ, the formation of
neuritic plaques, and the development of the CAA pathology
i nm o u s em o d e l so fA D[ 138–140]( Figure 2). All these data
suggest that cholesterol is implicated in the development of
AD and vascular dementia, though the mechanisms involved
remain elusive.
7.Cholesterol andNeuropathology
Several diﬀerent studies have provided converging evidence
for a link between vascular injury and AD in the brain.
AD and vascular dementia have been demonstrated to
be coexisting processes that contribute to the expression
of dementia [141]. Hypertension, diabetes mellitus, and
hypercholesterolemia are generally associated with a high
risk of developing AD [141–144]. Additionally, a growing
body of evidence suggests a connection between cholesterol
metabolism and susceptibility to AD, as well as increased
cholesterol release through synaptic degeneration [145–
148]. In rat hippocampal neuron cultures, reduction of
intracellular cholesterol levels has been shown to inhibit
the production of Aβ [149]. Studies with double trans-
genic (APP-presenilin) mice have shown that high dietary
cholesterol increases Aβ accumulation [150], and cholesterol
lowering agents increase processing of APP through the
nonamyloidogenic α-secretase pathway in diﬀerent cell lines
via increased membrane ﬂuidity [151]. Moreover, animals
fed high-cholesterol diets have shown to have increased
brain Aβ levels which are reduced when animals return
to normal chow diets [74]. It has been hypothesized that
cholesterol may inﬂuence the Aβ metabolism via indirect
eﬀects on vasculature, since high plasma cholesterol may
contribute to the development of AD via hypoperfusion6 Current Gerontology and Geriatrics Research
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Figure 2: Factors that inﬂuence in the progression of normal and pathological brain aging. The scheme shows how the interaction between
diﬀerent dietary and genetic factors (ApoE alleles) leads to diﬀerent ﬁnal outcomes in regards to brain aging.
of the brain promoting the elevated production of Aβ
[152–154], followed by cerebrovascular degeneration and
CAA. Furthermore, high plasma concentrations of choles-
terol in midlife, as opposed to later life, may determine
the risk of developing late onset AD. Mediterranean diet
(i.e., intake of ﬁsh omega-3 polyunsaturated fatty acids,
olive oil and unreﬁned foods, moderate intake of red wine
which contains polyphenols and other antioxidants, and
low intake of hydrogenated fats) has been associated with
reducing the risk of developing AD and other types of
dementia, but it has not been deﬁned yet whether this
eﬀect is by the diet-induced decrease of plasma LDL or
through additional properties of these kind of lipids, such
as anti-inﬂammatory properties [155]. It has been shown
that docosahexanoic acid may have a protective eﬀect
by maintaining vascular health [156–158]. Other studies
have shown that a high-cholesterol environment promotes
a reduced production of soluble APP [151, 159]. The
molecular basis by which cholesterol aﬀects Aβ production
is not clear yet. It has been suggested that cholesterol might
cause changes in membrane properties which could aﬀect
membrane-bound enzymes such as those that produce the
Aβ [160, 161].
The etiology of Parkinson’s disease (PD) and related
diseases such as dementia with Lewy bodies (DLB) is poorly
understood, although epidemiologic evidence suggests that
dietary factors may contribute to the development of PD
[162]. Dietary fats, including cholesterol, have been associ-
ated with PD in some studies and are believed to contribute
to oxidative stress [163]. However, other studies have also
shown either no association [164–166] or an increased
risk for PD based on dietary fat [167]. Surprisingly, high-
plasma cholesterol levels have recently been related to a
decreased PD risk [168, 169]. As discussed previously in
this review, ApoE ε4 allele represents a high-risk factor for
AD. However, a high prevalence of the ApoE ε4a l l e l e ,w i t h
its cholesterol disturbances associated, has also been found
in vascular dementia and DLB [170–172]. The possession
of this allele is associated with high plasma levels of total
cholesterol and LDL-cholesterol, both known to be risk
factors for developing atherosclerosis, and it is thought
that atherogenesis together with neurodegenerative mech-
anisms may inﬂuence the development of dementia [173]
(Figure 2).
8. Cholesterol and Neuroinﬂammation
It is now known that cholesterol-related disorders such
as atherosclerosis as well as AD and many other neu-
rodegenerative diseases all involve inﬂammatory processes.
Atherosclerosis-related inﬂammation involves changes in
the endothelium provoked by oxidized lipids and lipopro-
teins, monocyte and macrophage accumulation, and ﬁnally
sclerotic plaque formation [174]. Inﬂammatory processes
have also been linked to AD since cytokines and other
inﬂammatory mediators have been found in vulnerable
regions of AD brains [175–177]. The inﬂuence of high
cholesterol levels in plasma on cognitive performance has
been studied in mice, particularly from the point of view
of neuroinﬂammation and APP processing. It has been
found that high-fat/high cholesterol diet impairs working
memory in normal mice and induces neuroinﬂammation
with glial activation and increased expression of cytokines
and oxidative stress-related enzymes (TNFα,I L - 1 β,I L - 6 ,
iNOS and COX2) [178]. Importantly, neuroinﬂammatory
changes in the hypercholesterolemic mice are closely corre-
lated with behavioral changes so it has been suggested that
cholesterol-induced neuroinﬂammation may play a causal
role in memory dysfunction [178]. It has been shown
that cholesterol is able to induce Aβ production; however,
it is thought that cholesterol-induced neuroinﬂammation
would be more related to vascular alterations than to the
production of Aβ itself. It has been hypothesized that high
cholesterol levels in plasma may cause cerebrovasculature
dysfunction thus triggering the activation of perivascular
microglia with scavenger functions in the brain [179]. It is
thoughtthattherecruitmentofimmunecellstotheinﬂamed
brain arterioles may hence initiate a series of events leading
to an altered amyloid processing, neurodegeneration, and
synaptic and cognitive dysfunction. In addition, it is believed
that high cholesterol levels in plasma may induce vascular
changes as those observed in early inﬂammatory lesions of
atherosclerosis as well as an increase in BBB permeability.
Studies in rabbits have shown that cholesterol is able to
induce Aβ a n di r o nd e p o s i t i o ni nc e r e b r a lc o r t e xt o g e t h e r
with BBB disruption [180]. It has been also suggested that
inﬂammatorystimuliareablenotonlytoprovokeneurotoxic
and synaptotoxic eﬀect but also to induce amyloid genera-
tion, since up-regulating BACE1 [181, 182]. On the otherCurrent Gerontology and Geriatrics Research 7
hand, APP metabolism itself seems to regulate cholesterol
homeostasis through the regulation of the expression of LDL
receptor-relatedprotein-1[183].Interestingly,itappearsthat
AD brains do not contain increased levels of cholesterol
[184].
9. Cholesterol and CerebralOxidativeStress
Several studies have shown that high fat/high caloric diets
which lead to hyperlipidemic states increase the free radical
generation [185] and protein oxidation in the brain of
rodents [186]. Additionally, they clearly suggest a rela-
tionship between AD and hypercholesterolemia, in addi-
tion to coronary artery disease and hypertension [187].
It has been reported that hypercholesterolemia increases
the levels of reactive oxygen species so it is possible that
hypercholesterolemia facilitates the disease development of
the neurodegenerative disease through increased oxidant
production [188].
Reactive oxygen species are normal byproducts in cells
duringaerobicmetabolism[189],whosegenerationistightly
controlled, but when overproduced then a phenomenon
of oxidative stress is observed [190, 191]. Reactive oxygen
species are known to interact with proteins, lipids, and
nucleic acids, modifying not only their structure but their
f u n c t i o n sa sw e l l[ 192]. A great body of evidence has
demonstrated that high-fat diet-induced hyperlipidemia has
tight relations with vascular damage and oxidative stress
[15]. Hyperlipidemia has been shown to incite endothelial
cell activation, lipid deposit, and oxidative stress, throughout
the microvasculature [193, 194]. Both experimental and
clinicalstudieshavesuggestedthatoxidativestressisinvolved
in the pathogenesis of a number of diseases [194–197]
and that high-fat diets promote liver injury and insulin
resistance through oxidative stress [198–200], with increased
production of reactive oxygen species causing lipid peroxida-
tion followed by inﬂammatory response [201, 202]. Studies
performed in rabbits fed high-cholesterol diets have shown
an increase in several markers of oxidative stress, especially
in hippocampus, suggesting that hypercholesterolemic diet
is able to induce neuropathological-oxidative changes in the
brain [188].
10. Statins
The role of hypercholesterolemia in the pathogenesis of
coronary heart disease has been clearly established, and there
is a great body of clinical and epidemiological evidence sug-
gesting that lowering cholesterol with HMG-CoA reductase
inhibitors (“statins”) reduces coronary events. As previously
mentioned, statins act mainly by inhibiting HMG-CoA
reductase, the rate-limiting enzyme in cholesterol synthesis.
This inhibition leads to an up-regulation of hepatic LDL
receptor and concomitant removal of total and LDL choles-
terol from plasma [203]. Lowering circulating cholesterol
creates a cholesterol gradient across the BBB so an eﬄux
of cholesterol in the form of 24S-hydroxycholesterol occurs
from the brain.
However, statins also seem to have several diﬀerent
mechanisms of action that may contribute to their clinical
beneﬁt. Statins have been shown to inhibit accumula-
tion of cholesterol in macrophages in vitro [204], reduce
macrophage foam cell formation [205], and inhibit choles-
terol accumulation in vascular smooth muscle cells [206].
Additionally, statins have been shown to modify platelet
activity in hypercholesterolemic patients [207, 208], an
important feature since patients with high LDL cholesterol
levels show increased platelet aggregability. Many studies
have also suggested that statins, in addition to their role
in prevention of vascular events as mentioned previously,
have further mechanisms of action that may modify brain
injury before, during, and after cerebral ischemia. One of
the mechanisms would be the suppression of nitric oxide
production, a well-known component of the inﬂammatory
response [209]. Many cytokines are produced by neu-
rons, glia, and endothelium as mediators of inﬂammatory
response in the brain, and statins have been shown to reduce
the elaboration of these potentially detrimental cytokines
from macrophages [210]. Indeed, statins have been shown
to inhibit neutrophil adhesion to coronary endothelium
[211] and reduce leukocyte-endothelium interactions in
hypercholesterolemic animals [212]. A number of studies
have suggested that statins reduce lipoprotein oxidation and
ameliorate free radical injury, both of which have been
found to be implicated in brain injury, particularly during
reperfusion after an ischemic event.
As cholesterol levels have been related to AD develop-
ment, many studies have identiﬁed statin treatment as a
potential AD therapy. Some studies have shown statins to
be associated with increased activity of alpha secretase and
decreased concentrations of extracellular Aβ [213]. Another
interesting point is that statins may also modify the synaptic
plasma membrane distribution of cholesterol with reduction
in the cholesterol content of the exofacial leaﬂet [214]. By
stabilizing the cholesterol distribution in the membrane
leaﬂet, statins may prevent cleavage of APP into pathological
Aβ isoforms[214].Twoepidemiologicalstudiesinvestigating
the prevalence of dementia among statins users have shown
that statins are associated with a lower risk of dementia,
with one study reporting a relative risk reduction [215, 216].
However, although statin treatment seems to be beneﬁcial
for lowering cholesterol levels, potential adverse eﬀects
have been attributed such as increased risk of intracerebral
hemorrhage and cognitive impairment [217]. On the other
hand, several animal studies have also reported potential
neurotoxicity with statin use [218, 219].
11. Conclusions
There are clear direct and indirect roles for cholesterol
in regulating the development of age-related dementia.
Treatment with statins is not a clear solution to preventing
the deleterious eﬀects of high cholesterol on the brain, as
chronic statin use may adversely aﬀect the aging brain.
Understanding the mechanisms by which cholesterol and
statins mediate their eﬀects on brain is therefore a growing
and important area of future research.8 Current Gerontology and Geriatrics Research
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